Journal of Clinical Oncology, Vol 13, 1470-1477, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

T Jansson, JE Westlin, H Ahlstrom, A Lilja, B Langstrom and J Bergh
Department of Oncology, Akademiska Sjukhuset, University Hospital, Uppsala, Sweden.

PURPOSE: To investigate if sequential positron emission tomographic (PET) scans with the glucose analog 18F-2-fluoro-2-deoxy-D-glucose (18FDG) and/or L-methyl-11C-methionine (11C-methionine) in patients with breast cancer could provide early information on the efficacy of polychemotherapy. PATIENTS AND METHODS: Sixteen patients with breast cancer (11 with locally advanced tumors, three with recurrent disease in the contralateral breast, two of them with distant and regional metastases, and two with distant metastases) underwent a baseline and two follow-up PET scans after the first and third/fourth polychemotherapy course. Tumor response was determined clinically/radiographically after three/four polychemotherapy courses. RESULTS: Five patients were investigated with 18FDG, seven with both 11C-methionine and 18FDG, and four with only 11C-methionine before polychemotherapy. 11C-methionine presented a more distinct visualization of primary/contralateral breast cancers in five of seven patients when compared with 18FDG. Twelve of 16 patients demonstrated a response using conventional methods after the third/fourth course of polychemotherapy. Eight of these 12 clinical responders had a significant decrease in tracer uptake at the first PET scan performed 6 to 13 days after the first polychemotherapy course, and these reductions were further augmented after the third/fourth course and corresponded to the conventional therapy evaluation (clinical examination, computed tomography [CT], ultrasonography, and mammography). CONCLUSION: Our data indicate that PET may be of clinical value in predicting response to chemotherapy in patients with locally advanced breast cancer and/or metastatic disease earlier than any other method used.

This article has been cited by other articles:

				U. Tateishi, C. Gamez, S. Dawood, H. W. D. Yeung, M. Cristofanilli, and H. A. Macapinlac Bone Metastases in Patients with Metastatic Breast Cancer: Morphologic and Metabolic Monitoring of Response to Systemic Therapy with Integrated PET/CT Radiology, April 1, 2008; 247(1): 189 - 196. [Abstract] [Full Text] [PDF]

				H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213. [Abstract] [Full Text] [PDF]

				R. J. Francis, M. J. Byrne, A. A. van der Schaaf, J. A. Boucek, A. K. Nowak, M. Phillips, R. Price, A. P. Patrikeos, A. W. Musk, and M. J. Millward Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans J. Nucl. Med., September 1, 2007; 48(9): 1449 - 1458. [Abstract] [Full Text] [PDF]

				W.-A. Hsueh, A. L. Kesner, A. Gangloff, M. D. Pegram, M. Beryt, J. Czernin, M. E. Phelps, and D. H.S. Silverman Predicting Chemotherapy Response to Paclitaxel with 18F-Fluoropaclitaxel and PET J. Nucl. Med., December 1, 2006; 47(12): 1995 - 1999. [Abstract] [Full Text] [PDF]

				C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372. [Abstract] [Full Text] [PDF]

				O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443. [Abstract] [Full Text] [PDF]

				W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]

				I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]

				W A Weber PET for response assessment in oncology: radiotherapy and chemotherapy Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49. [Abstract] [Full Text] [PDF]

				J. Dose Schwarz, M. Bader, L. Jenicke, G. Hemminger, F. Janicke, and N. Avril Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET J. Nucl. Med., July 1, 2005; 46(7): 1144 - 1150. [Abstract] [Full Text] [PDF]

				A. Quon and S. S. Gambhir FDG-PET and Beyond: Molecular Breast Cancer Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673. [Full Text] [PDF]

				J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837. [Abstract] [Full Text] [PDF]

				J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF]

				R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527. [Abstract] [Full Text] [PDF]

				T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno Bone Imaging in Metastatic Breast Cancer J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953. [Abstract] [Full Text] [PDF]

				H. Zhang, K. Yoshikawa, K. Tamura, T. Tomemori, K. Sagou, M. Tian, S. Kandatsu, T. Kamada, H. Tsuji, T. Suhara, et al. [11C]Methionine Positron Emission Tomography and Survival in Patients with Bone and Soft Tissue Sarcomas Treated by Carbon Ion Radiotherapy Clin. Cancer Res., March 1, 2004; 10(5): 1764 - 1772. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, E. K. Schubert, J. Tseng, T. J. Lawton, H. M. Linden, and R. B. Livingston Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2003; 44(11): 1806 - 1814. [Abstract] [Full Text] [PDF]

				W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657. [Abstract] [Full Text] [PDF]

				E. Chesnay, E. Babin, J. M. Constans, D. Agostini, A. Bequignon, A. Regeasse, F. Sobrio, and S. Moreau Early Response to Chemotherapy in Hypopharyngeal Cancer: Assessment with 11C-Methionine PET, Correlation with Morphologic Response, and Clinical Outcome J. Nucl. Med., April 1, 2003; 44(4): 526 - 532. [Abstract] [Full Text] [PDF]

				L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]

				L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]

				R. J. Downey, T. Akhurst, D. Ilson, R. Ginsberg, M. S. Bains, M. Gonen, H. Koong, M. Gollub, B. D. Minsky, M. Zakowski, et al. Whole Body 18FDG-PET and the Response of Esophageal Cancer to Induction Therapy: Results of a Prospective Trial J. Clin. Oncol., February 1, 2003; 21(3): 428 - 432. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, A. Charlop, T. J. Lawton, E. K. Schubert, J. Tseng, and R. B. Livingston Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy J. Nucl. Med., April 1, 2002; 43(4): 500 - 509. [Abstract] [Full Text] [PDF]

				H. A. Nabi and J. M. Zubeldia Clinical Applications of 18F-FDG in Oncology J. Nucl. Med. Technol., March 1, 2002; 30(1): 3 - 9. [Abstract] [Full Text] [PDF]

				R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al. Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387. [Abstract] [Full Text] [PDF]

				W. B. Eubank, D. A. Mankoff, J. Takasugi, H. Vesselle, J. F. Eary, T. J. Shanley, J. R. Gralow, A. Charlop, G. K. Ellis, K. L. Lindsley, et al. 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3516 - 3523. [Abstract] [Full Text] [PDF]

				C. Muhr, O. Gudjonsson, A. Lilja, M. Hartman, Z.-J. Zhang, and B. Langstrom Meningioma Treated with Interferon-{alpha}, Evaluated with [11C]-L-Methionine Positron Emission Tomography Clin. Cancer Res., August 1, 2001; 7(8): 2269 - 2276. [Abstract] [Full Text] [PDF]

				S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]

				N. Avril, C. A. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, and M. Schwaiger Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations J. Clin. Oncol., October 20, 2000; 18(20): 3495 - 3502. [Abstract] [Full Text] [PDF]

				I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]

				M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]

				K. Murthy, M. Aznar, A. M. Bergman, C. J. Thompson, J. L. Robar, R. Lisbona, A. Loutfi, and J. H. Gagnon Positron Emission Mammographic Instrument: Initial Results Radiology, April 1, 2000; 215(1): 280 - 285. [Abstract] [Full Text]

				W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose Blood, June 15, 1998; 91(12): 4464 - 4471. [Abstract] [Full Text] [PDF]